REG - Oncimmune Hldgs PLC - Trading Update

Oncimmune HoldingsAnnouncement

31/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250131:nRSe3699Va&default-theme=true

RNS Number : 3699V  Oncimmune Holdings PLC  31 January 2025

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Trading Update

 

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company providing research services to the pharmaceutical and biotechnology industry to enable the delivery of precision medicine, provides a trading update for FY2024 and FY2025 (years ending 31 August 2024 and 2025 respectively).

 

FY2024 Results

 

As detailed in the update of 9 September 2024, Oncimmune remains on track to
report revenue of approximately £3m for FY2024, showing over 100% growth on
the prior year (£1.15m in FY2023 from continuing operations).  Publication
of the FY2024 results is expected by mid-February.

 

 

Outlook  for FY2025

 

In the last trading update of 31 October 2024, the Company reported three new
contracts with a total value of £0.34m, continuing the positive commercial
traction seen in the last quarter  of FY2024.

 

Revenue for the first half of FY2025 is likely to be approximately £1.4m, an
increase of circa 20% on the prior year  (£1.19m) and the Company continues
to add to its broad pipeline of potential contracts.

 

Oncimmune has recently added one new contract with a new customer and has 11
others under negotiation, representing a total of up to £2.0m of potential
revenue. It also has earlier stage discussions ongoing with existing customers
for follow-on work, some of which would be expected to start in FY2025.
However, and in line with the rest of the Pharma services outsourcing market,
conversion of new contracts has been slower than since late 2024.  At the
same time as vigorously pursuing follow-on work, Oncimmune is discussing a
number of significant strategic collaborations and transformative contracts
with several parties which, whilst there is no certainty, could materially
improve its revenue position in FY2025.

 

Since the last trading update of 31 October 2024, Oncimmune has had one
potential contract deferred into FY2026 and one removed from its pipeline.
As a result, with seven months of the financial year still to go, Oncimmune
now anticipates FY2025 revenue to be in the region of £4m, which would be an
uplift of 33% vs FY2024 and growth of around 250% vs FY2023.  Oncimmune
expects to have much greater visibility on its revenue in the second half of
the financial year.

 

The Company has already taken actions to ensure its overheads and debt service
costs will be significantly  lower in FY2025 than in FY2024, resulting in a
cost base of around £5m. As at 31 January 2025, the Company has cash balances
of over £1m and has paid down some debt such that only £1.5m of the
principal loan remains outstanding as at 31 January 2025.

 

With a revised outlook for FY2025, the Board is exploring strategic
partnerships and business synergies to build its critical mass and in parallel
to seek additional finance to extend its cash runway.

 

 

Martin Gouldstone, CEO of Oncimmune said:

 

"Following the substantial revenue growth seen between FY2023 and FY2024, our
focus remains on delivery of world-class results for our customers on existing
projects, and the pursuit and conversion of other opportunities with existing
and new customers.  We remain optimistic and are pursuing several
opportunities which could be transformative for the business."

 

This announcement contains inside information for the purposes of Regulation
11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as
amended). Upon the publication of this announcement via a Regulatory
Information Service, this inside information is now considered to be in the
public domain.

 

For further information:

 

Oncimmune Holdings plc

contact@oncimmune.com (mailto:contact@oncimmune.com)

 

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)

Nigel Birks, Ondraya Swanson (ECM)

+44 (0) 20 7220 0500

 

Zeus (Joint Broker)

Dominic King

+44 (0)20 3829 5000

+44 (0)20 3727 1000

 

About Oncimmune

 

Oncimmune is a precision medicine company, specialising in analysing immune
interactions through the autoantibody profile. Taking a platform approach to
generating insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations (CROs) to
discover novel biomarkers for the development of more targeted and effective
therapies across many immune-mediated diseases. Our mission at Oncimmune is to
enable precision medicine. We help our partners to discover novel biomarkers,
drug targets and predict treatment efficacy through the application of our
platform. We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of experience in the
field. Our aim is to make this an essential tool in drug discovery and
development.

 

Oncimmune is headquartered in the UK, with its discovery and development
facility based in Dortmund, Germany and a business development team based in
the US and Europe.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTSDLEESEISELF